Second TDM of biologics symposium another success!

Last Friday, 7 Dec 2018, the second therapeutic drug monitoring (TDM) of biologics symposium organised by Sanquin and Amsterdam UMC attracted an international audience (head count almost 250). Clinicians and scientists from industry and academia shared their view on TDM of biologics.

It was widely recognised that TDM could help optimal use of biologics. Interesting was to learn that success rate to bring biologics to market is a lot higher than for small molecules: this means we can expect a sustained pipeline in biologics.

New: oncology

panel discussion TDMA panel discussion revealed that how to implement TDM of biologics per discipline: although gastroenterologist, dermatologist and rheumatologists agreed on the benefit of TDM- not all used the data in the same way. The first symposium was restricted to inflammatory diseases: oncology made a clear entrance and is a new and exciting area for the use of TDM in biologics.

Like two years ago- it was a thrill to have a lot of like-minded experts from industry, academia and the clinic in one meeting to exchange thoughts and start new collaborations. We sincerely hope to organise a third symposium!